Apart from its impact on LDL-C levels, PCSK9 inhibitor also exhibits potential pleiotropic effects such as enhancing tumor response to immune checkpoint therapy, inhibiting platelet activation and thrombosis, and reducing apoptosis (18, 48, 49). The gene discussed is PCSK9; the disease is neoplasm.